EA004800B1 - Способ лечения диабета росиглитазоном и инсулином - Google Patents

Способ лечения диабета росиглитазоном и инсулином Download PDF

Info

Publication number: EA004800B1
Authority: EA; Eurasian Patent Office
Prior art keywords: compound; pharmaceutically acceptable; diabetes; acceptable form; insulin
Prior art date: 1997-06-18

Application number

EA200000042A

Other languages

English (en)

Russian (ru)

Other versions

EA200000042A1 (ru

Inventor

Стефен Элистэр Смит

Original Assignee

Смитклайн Бичам Плс

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-18

Filing date

1998-06-15

Publication date

2004-08-26

1998-06-15 Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс

2000-08-28 Publication of EA200000042A1 publication Critical patent/EA200000042A1/ru

2004-08-26 Publication of EA004800B1 publication Critical patent/EA004800B1/ru

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 54
102000004877 Insulin Human genes 0.000 title claims abstract description 27
108090001061 Insulin Proteins 0.000 title claims abstract description 27
229940125396 insulin Drugs 0.000 title claims abstract description 27
238000011282 treatment Methods 0.000 title claims abstract description 18
206010012601 diabetes mellitus Diseases 0.000 title abstract description 20
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title 2
229960004586 rosiglitazone Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 70
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 27
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 11
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
238000004519 manufacturing process Methods 0.000 claims abstract 6
-1 (2-pyridyl) amino Chemical group 0.000 claims description 9
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 37
238000000034 method Methods 0.000 description 29
239000003826 tablet Substances 0.000 description 13
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
206010022489 Insulin Resistance Diseases 0.000 description 5
235000008504 concentrate Nutrition 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
229920003109 sodium starch glycolate Polymers 0.000 description 5
239000008109 sodium starch glycolate Substances 0.000 description 5
229940079832 sodium starch glycolate Drugs 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000008187 granular material Substances 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000012453 solvate Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229960001021 lactose monohydrate Drugs 0.000 description 2
150000002688 maleic acid derivatives Chemical class 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
150000001467 thiazolidinediones Chemical class 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
STGNLGBPLOVYMA-TZKOHIRVSA-N (z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O STGNLGBPLOVYMA-TZKOHIRVSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
230000003749 cleanliness Effects 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000008213 purified water Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)

EA200000042A 1997-06-18 1998-06-15 Способ лечения диабета росиглитазоном и инсулином EA004800B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9712866.4A GB9712866D0 (en)	1997-06-18	1997-06-18	Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en)	1997-06-18	1998-06-15	Treatment of diabetes with rosiglitazone and insulin

Publications (2)

Publication Number	Publication Date
EA200000042A1 EA200000042A1 (ru)	2000-08-28
EA004800B1 true EA004800B1 (ru)	2004-08-26

Family

ID=10814527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA200000042A EA004800B1 (ru)	1997-06-18	1998-06-15	Способ лечения диабета росиглитазоном и инсулином

Country Status (30)

Country	Link
EP (1)	EP0999837A1 (cs)
JP (1)	JP2002504138A (cs)
KR (1)	KR20010013843A (cs)
CN (1)	CN1133431C (cs)
AP (1)	AP1287A (cs)
AR (2)	AR012997A1 (cs)
AU (1)	AU8216398A (cs)
BG (1)	BG104059A (cs)
BR (1)	BR9810444A (cs)
CA (1)	CA2294141A1 (cs)
CO (1)	CO4940454A1 (cs)
DZ (1)	DZ2521A1 (cs)
EA (1)	EA004800B1 (cs)
GB (1)	GB9712866D0 (cs)
HU (1)	HUP0003260A3 (cs)
ID (1)	ID23951A (cs)
IL (1)	IL133143A0 (cs)
IN (1)	IN189723B (cs)
MA (1)	MA26511A1 (cs)
NO (1)	NO996265L (cs)
OA (1)	OA11517A (cs)
PE (1)	PE104499A1 (cs)
PL (1)	PL343123A1 (cs)
SK (1)	SK179399A3 (cs)
TR (1)	TR199903095T2 (cs)
TW (1)	TW587937B (cs)
UA (1)	UA70299C2 (cs)
UY (1)	UY25050A1 (cs)
WO (1)	WO1998057636A1 (cs)
ZA (1)	ZA985237B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6291495B1 (en) *	1997-02-24	2001-09-18	Robert B. Rieveley	Method and composition for the treatment of diabetes
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
TWI249401B (en)	1999-04-14	2006-02-21	Takeda Chemical Industries Ltd	Agent for improving ketosis
AU765498B2 (en)	1999-04-23	2003-09-18	Smithkline Beecham Plc	Novel pharmaceutical
US6660716B1 (en) *	1999-06-21	2003-12-09	Eli Lilly And Company	Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
CA2369839A1 (en) *	1999-06-25	2001-01-04	Minimed, Inc.	Compositions of insulin and insulin-related peptide for treating diabetes
US6468507B1 (en) *	2000-05-01	2002-10-22	Aeropharm Technology, Inc.	Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) *	2000-09-29	2000-11-15	Smithkline Beecham Plc	Novel pharmaceutical
AU2002248464A1 (en)	2001-02-21	2002-09-12	Medtronic Minimed, Inc.	Stabilized insulin formulations
US6531461B1 (en)	2001-06-04	2003-03-11	Louis Obyo Obyo Nelson	Medicament for the treatment of diabetes
WO2002100396A1 (en) *	2001-06-07	2002-12-19	Wyeth	COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en)	2001-06-28	2004-05-18	Metronic Minimed, Inc.	Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
ES2295692T3 (es) *	2002-11-08	2008-04-16	F. Hoffmann-La Roche Ag	Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
US7264813B2 (en)	2003-09-24	2007-09-04	Nikken Sohonsha Corporation	Therapeutic uses of Dunaliella powder
CN102389427A (zh) *	2011-10-10	2012-03-28	成都恒瑞制药有限公司	含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0719140T3 (da) *	1993-09-15	2008-03-03	Daiichi Sankyo Co Ltd	Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM
CN1192683A (zh) *	1995-08-10	1998-09-09	沃尼尔·朗伯公司	减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
DK0859608T3 (da) *	1995-09-18	2004-06-14	Ligand Pharm Inc	Behandling af NIDDM med RXR-agonister

1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
1998
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Ceased
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Ceased
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
1999
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
- 1999-12-17 NO NO996265A patent/NO996265L/no not_active Application Discontinuation
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown

Also Published As

Publication number	Publication date
ID23951A (id)	2000-06-08
GB9712866D0 (en)	1997-08-20
PE104499A1 (es)	2000-01-13
HUP0003260A3 (en)	2001-12-28
AU8216398A (en)	1999-01-04
CN1133431C (zh)	2004-01-07
DZ2521A1 (fr)	2003-02-08
TR199903095T2 (xx)	2000-08-21
AP1287A (en)	2004-06-26
ZA985237B (en)	2000-02-17
KR20010013843A (ko)	2001-02-26
HUP0003260A2 (hu)	2001-05-28
OA11517A (en)	2004-02-04
AP9901718A0 (en)	1999-12-31
EA200000042A1 (ru)	2000-08-28
MA26511A1 (fr)	2004-12-20
AR012997A1 (es)	2000-11-22
SK179399A3 (en)	2000-11-07
CN1260715A (zh)	2000-07-19
IL133143A0 (en)	2001-03-19
PL343123A1 (en)	2001-07-30
TW587937B (en)	2004-05-21
NO996265D0 (no)	1999-12-17
UY25050A1 (es)	2000-09-29
BR9810444A (pt)	2000-09-05
UA70299C2 (en)	2004-10-15
WO1998057636A1 (en)	1998-12-23
IN189723B (cs)	2003-04-19
BG104059A (en)	2000-10-31
CO4940454A1 (es)	2000-07-24
NO996265L (no)	1999-12-17
EP0999837A1 (en)	2000-05-17
JP2002504138A (ja)	2002-02-05
CA2294141A1 (en)	1998-12-23
AR015894A1 (es)	2001-05-30

Legal Events

Date	Code	Title	Description
2006-04-28	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM RU

Publication	Publication Date	Title
KR100666591B1 (ko)	2007-01-11	티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
SK285484B6 (sk)	2007-02-01	Kombinácia obsahujúca 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, inzulínový sekrečný promótor a biguanidovú antihyperglykémickú látku, farmaceutický prostriedok s jej obsahom a ich použitie na liečbu diabetu
SK179399A3 (en)	2000-11-07	Use of insulin sensitiser and an insulin
EP0999845B1 (en)	2007-02-14	Treatment of diabetes with thiazolidinedione and sulphonylurea
SK602000A3 (en)	2000-07-11	Application of insulin sensitiser and sub-maximal amount of an insulin secretagogue for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition
SK179499A3 (en)	2000-11-07	The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
US20020028768A1 (en)	2002-03-07	Treatment of diabetes with rosiglitazone and insulin
MXPA99012065A (en)	2000-08-01	Treatment of diabetes with rosiglitazone and insulin
NZ518076A (en)	2004-02-27	5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
UA68352C2 (en)	2004-08-16	Method for treatment of diabetes mellitus with thiazolidin and metformin
MXPA99012098A (en)	2000-08-01	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CZ9904579A3 (cs)	2001-06-13	Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
HK1028200B (en)	2007-10-05	Treatment of diabetes with thiazolidinedione and sulphonylurea